Holen Sie sich die Stockscreener-App
8.55
0.59%
0.05
Vorhandelsmarkt:
8.32
-0.23
-2.69%
Schlusskurs vom Vortag:
$8.50
Offen:
$8.56
24-Stunden-Volumen:
2.25M
Relative Volume:
1.51
Marktkapitalisierung:
$744.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-3.9401
EPS:
-2.17
Netto-Cashflow:
$-138.01M
1W Leistung:
-0.12%
1M Leistung:
+5.95%
6M Leistung:
+5.17%
1J Leistung:
+16.64%
1-Tages-Spanne:
$8.16
$8.62
1-Wochen-Bereich:
$8.16
$8.76
52-Wochen-Spanne:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
8.55 | 739.65M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Eingeleitet | Guggenheim | Neutral |
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Kura Oncology Q4 Earnings Summary & Key Takeaways - Benzinga
Cancer pill KOMZIFTI begins sales as Kura posts $81M loss - Stock Titan
Kura Oncology at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Kura Oncology (KURA) Set to Release Q4 Earnings - GuruFocus
A Glimpse of Kura Oncology's Earnings Potential - Benzinga
Kura Oncology Inc expected to post a loss of 61 cents a shareEarnings Preview - TradingView
Kura Oncology (KURA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Wall Street Zen Downgrades Kura Oncology (NASDAQ:KURA) to Sell - MarketBeat
(KURA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Kura Oncology (NASDAQ:KURA) Upgraded at Zacks Research - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
KURA Should I Buy - Intellectia AI
Kura Oncology, Inc. (KURA): Investor Outlook Reveals 275% Upside Potential - DirectorsTalk Interviews
KURA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Cancer-focused biopharma Kura Oncology sets March 5 call on 2025 results - Stock Titan
Kura Oncology to Participate in Three Upcoming Investor Conferences - marketscreener.com
Biotech firm Kura Oncology maps three March investor talks - Stock Titan
Kura Oncology (NASDAQ:KURA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Will Kura Oncology Inc. stock benefit from upcoming earnings reportsPrice Action & Consistent Profit Focused Trading Strategies - mfd.ru
Kura Oncology, Inc. (KURA): Investor Outlook With A Promising 278% Potential Upside - DirectorsTalk Interviews
Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to Decline - Finviz
Kura Oncology (KURA) to Release Quarterly Earnings on Wednesday - MarketBeat
Liquidity Mapping Around (KURA) Price Events - Stock Traders Daily
Kura Oncology (NASDAQ:KURA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
What is Kura Oncology Inc. s P E ratio telling us2025 Price Targets & Accurate Entry and Exit Point Alerts - mfd.ru
Kura Oncology (NASDAQ:KURA) Share Price Crosses Below 50-Day Moving AverageHere's Why - MarketBeat
IPO Launch: Is Kura Oncology Inc a strong candidate for buy and holdJuly 2025 Retail & Free Verified High Yield Trade Plans - baoquankhu1.vn
Is Kura Oncology Inc. vulnerable to short sellersPortfolio Return Report & Daily Price Action Insights - mfd.ru
The Truth About Kura Oncology Inc: Is This Sleeper Cancer Stock About To Explode? - AD HOC NEWS
Kura Oncology (KURA) Issues Stock Options to New Employees - GuruFocus
Kura Oncology Grants Inducement Stock Options to New Employees as Part of 2023 Inducement Option Plan - Quiver Quantitative
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Need To Know: The Consensus Just Cut Its Kura Oncology, Inc. (NASDAQ:KURA) Estimates For 2026 - simplywall.st
Why (KURA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Barclays Remains a Buy on Kura Oncology (KURA) - The Globe and Mail
Analyst flags Kura Oncology, Inc. (KURA) for 2026 milestones and pipeline expansion - MSN
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion - Finviz
Citizens reiterates Market Outperform rating on Kura Oncology stock By Investing.com - Investing.com Canada
ETF Watch: Is AVDL vulnerable to short sellers2025 Top Decliners & High Accuracy Investment Entry Signals - baoquankhu1.vn
Treasury Yields: Whats the profit margin of Kura Oncology IncWeekly Trend Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Nan Fung Trinity HK Ltd. Invests $2.04 Million in Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology, Inc. (KURA) Growth Potential: Analyst Ratings Suggest A 295.93% Upside - DirectorsTalk Interviews
Kura Oncology Tightens Governance with Amended Bylaws - TipRanks
Don't Ignore The Insider Selling In Kura Oncology - simplywall.st
Insider Selling: Kura Oncology (NASDAQ:KURA) Insider Sells 6,414 Shares of Stock - MarketBeat
Why is Kura Oncology Inc. stock going upWeekly Risk Report & Low Drawdown Trading Techniques - mfd.ru
Kura Oncology’s chief legal officer sells $94,827 in stock - Investing.com India
Kura oncology CSO Burrows sells $11k in shares By Investing.com - Investing.com Australia
Kura Oncology COO Ford sells $15,339 in stock By Investing.com - Investing.com UK
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):